Profile data is unavailable for this security.
About the company
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.
- Revenue in DKK (TTM)14.68bn
- Net income in DKK3.27bn
- Incorporated2000
- Employees6.07k
- LocationNovozymes A/SKrogshoejvej 36BAGSVAERD 2880DenmarkDNK
- Phone+45 44460000
- Fax+45 44469999
- Websitehttps://www.novozymes.com/
More ▼
Mergers & acquisitions
| Acquired company | NZYM B:CPH since announced | Transaction value |
|---|---|---|
| Precisionbiotics Ltd | -0.34% | 90.00m |
Data delayed at least 15 minutes, as of Aug 07 2020 15:59 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uralkaliy PAO | 15.45bn | 6.71bn | 43.71bn | 20.50k | 1.93 | 1.16 | 5.31 | 2.83 | 61.64 | 61.64 | 141.92 | 102.38 | 0.3182 | 2.85 | 7.07 | -- | 13.81 | 8.38 | 18.48 | 11.54 | 75.86 | 76.18 | 43.41 | 26.41 | 0.5262 | -- | 0.7165 | -- | 3.82 | 5.59 | 980.62 | -- | 11.78 | -- |
| Arkema SA | 61.53bn | 2.99bn | 51.50bn | 20.50k | 17.15 | 1.24 | 6.68 | 0.837 | 5.25 | 5.25 | 107.86 | 72.59 | 0.7885 | 6.07 | 6.47 | 402,740.50 | 4.03 | 5.45 | 4.87 | 6.75 | 20.18 | 21.56 | 5.11 | 6.15 | 2.06 | 5.81 | 0.3118 | 33.05 | -0.8848 | 7.98 | -27.15 | 24.07 | 6.34 | 3.53 |
| Brenntag AG | 92.44bn | 3.53bn | 59.42bn | 17.23k | 16.76 | 2.30 | 10.25 | 0.6427 | 3.08 | 3.08 | 80.56 | 22.49 | 1.47 | 7.89 | 6.83 | 709,381.40 | 5.66 | 5.52 | 7.61 | 7.56 | 22.44 | 21.50 | 3.84 | 3.49 | 1.25 | 9.79 | 0.4202 | 40.28 | 2.17 | 5.06 | 1.26 | 6.58 | 14.65 | 6.79 |
| Umicore SA | 148.04bn | 1.72bn | 69.72bn | 13.74k | 39.86 | 3.50 | 15.77 | 0.471 | 0.9527 | 0.9527 | 82.17 | 10.85 | 2.83 | 8.15 | 15.25 | 1,406,503.00 | 3.43 | 4.88 | 5.51 | 8.12 | 5.33 | 7.36 | 1.21 | 1.91 | 0.8759 | 5.52 | 0.4859 | 42.87 | 27.47 | 16.56 | -9.21 | 13.01 | 24.87 | -6.89 |
| Yara International ASA | 76.94bn | 2.40bn | 73.64bn | 16.03k | 30.93 | 1.47 | 8.93 | 0.9572 | 12.70 | 12.70 | 406.37 | 267.39 | 0.7206 | 3.62 | 6.85 | 6,864,293.00 | 2.23 | 3.98 | 2.85 | 5.00 | 29.39 | 25.78 | 3.10 | 4.86 | 1.29 | 2.56 | 0.3419 | 108.71 | -0.5415 | -3.13 | 276.73 | -13.11 | -0.8641 | -3.69 |
| Evonik Industries AG | 93.76bn | 4.59bn | 83.32bn | 32.47k | 18.21 | 1.27 | 7.48 | 0.8886 | 1.32 | 4.04 | 26.90 | 18.88 | 0.5888 | 4.36 | 8.05 | 388,181.20 | 2.97 | 4.17 | 3.61 | 5.05 | 27.73 | 31.01 | 5.04 | 5.96 | 1.11 | 13.50 | 0.3491 | 68.57 | -1.20 | 0.294 | 9.77 | 5.47 | -4.28 | 2.83 |
| Novozymes A/S | 14.68bn | 3.27bn | 87.16bn | 6.07k | 32.83 | 9.88 | 19.50 | 5.94 | 11.48 | 11.48 | 51.48 | 38.17 | 0.7193 | 2.42 | 4.96 | 2,516,544.00 | 16.04 | 16.37 | 21.44 | 21.18 | 55.73 | 57.48 | 22.30 | 21.52 | 0.9838 | 38.19 | 0.3472 | 42.19 | -0.1112 | 2.90 | -2.23 | 4.54 | 6.64 | 11.84 |
| Chr Hansen Holding A/S | 8.84bn | 1.89bn | 93.78bn | 3.42k | 49.55 | 14.96 | 38.37 | 10.61 | 14.35 | 14.35 | 67.25 | 47.55 | 0.5595 | 3.00 | 6.62 | 2,584,411.00 | 11.95 | 12.28 | 14.86 | 14.69 | 55.69 | 54.22 | 21.35 | 20.45 | 0.6206 | 25.85 | 0.5393 | 81.53 | 5.80 | 8.95 | 9.64 | 13.61 | 17.32 | 28.68 |
| Akzo Nobel NV | 64.70bn | 3.58bn | 116.90bn | 33.20k | 33.39 | 2.65 | 17.97 | 1.81 | 2.44 | 2.46 | 43.97 | 30.68 | 0.6284 | 4.08 | 3.71 | 256,952.70 | 3.73 | 3.91 | 5.00 | 5.61 | 43.51 | 42.98 | 5.94 | 6.10 | 1.22 | 30.74 | 0.3286 | 77.82 | 0.2161 | -8.29 | 29.25 | -0.4202 | -18.30 | 3.10 |
Data as of Aug 07 2020. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK
20.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2019 | 14.17m | 6.13% |
| MFS International (UK) Ltd.as of 30 Jun 2020 | 6.43m | 2.78% |
| The Vanguard Group, Inc.as of 30 Jun 2020 | 6.06m | 2.62% |
| Baillie Gifford & Co.as of 30 Jul 2020 | 5.68m | 2.46% |
| Harding Loevner LPas of 30 Jun 2020 | 2.93m | 1.27% |
| Walter Scott & Partners Ltd.as of 29 May 2020 | 2.78m | 1.20% |
| BlackRock Fund Advisorsas of 09 Jul 2020 | 2.67m | 1.15% |
| NNIP Advisors BVas of 31 Mar 2020 | 2.26m | 0.98% |
| Mawer Investment Management Ltd.as of 30 Apr 2020 | 2.21m | 0.96% |
| Impax Asset Management Ltd.as of 29 May 2020 | 2.16m | 0.93% |
More ▼
Data from 31 Dec 2019 - 31 Jul 2020Source: FactSet Research Systems Inc.
